menu
    • menu
    [{"orgOrder":0,"company":"SparingVision","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SparingVision \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SparingVision \/ Undisclosed"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"4BIO Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ 4BIO Capital","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ 4BIO Capital"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Jeito Capital","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Jeito Capital"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Tenpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Divestment","leadProduct":"SPVN20","moa":"GIRK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Tenpoint Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SparingVision \/ Tenpoint Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by SparingVision

    Menu

    SparingVision

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    SparingVision

    France arrow
    AAN
    Not Confirmed

    SparingVision

    France arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPVN06

    Therapeutic Area : Genetic Disease

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    SparingVision Completes Final Dose Escalation in PRODYGY Trial with SPVN06

    Details : SPVN06 is a mutation-agnostic AAV gene therapy approach comprising one neurotrophic factor (RdCVF) and one enzyme reducing oxidative stress. It is under development for treating Retinitis Pigmentosa.

    Product Name : SPVN06

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    January 24, 2024

    Lead Product(s) : SPVN06

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    SparingVision

    France arrow
    AAN
    Not Confirmed

    SparingVision

    France arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPVN20

    Therapeutic Area : Genetic Disease

    Study Phase : Preclinical

    Sponsor : Tenpoint Therapeutics

    Deal Size : Undisclosed

    Deal Type : Divestment

    DEALS_DEV arrow-down

    SparingVision Sells Ex Vivo GIRK Technology to Tenpoint Therapeutics

    Details : Through the divestment, Tenpoint has acquired SparingVision's ex vivo GIRK technology. SparingVision will remain focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate.

    Product Name : SPVN20

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    December 07, 2023

    Lead Product(s) : SPVN20

    Therapeutic Area : Genetic Disease

    Highest Development Status : Preclinical

    Sponsor : Tenpoint Therapeutics

    Deal Size : Undisclosed

    Deal Type : Divestment

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    SparingVision

    France arrow
    AAN
    Not Confirmed

    SparingVision

    France arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPVN06

    Therapeutic Area : Genetic Disease

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gen...

    Details : SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress used for the treatment of for the treatment of retinitis pigmentosa.

    Product Name : SPVN06

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    August 30, 2023

    Lead Product(s) : SPVN06

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    SparingVision

    France arrow
    AAN
    Not Confirmed

    SparingVision

    France arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPVN06

    Therapeutic Area : Genetic Disease

    Study Phase : IND Enabling

    Sponsor : Jeito Capital

    Deal Size : $75.0 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines ...

    Details : Proceeds from the financing will be used to fund the first-in-human trials of the Company’s two lead gene-independent assets, SPVN06 and SPVN20, as well as the development of genome editing assets through its collaboration with Intellia Therapeutics.

    Product Name : SPVN06

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    September 14, 2022

    Lead Product(s) : SPVN06

    Therapeutic Area : Genetic Disease

    Highest Development Status : IND Enabling

    Sponsor : Jeito Capital

    Deal Size : $75.0 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    SparingVision

    France arrow
    AAN
    Not Confirmed

    SparingVision

    France arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPVN06

    Therapeutic Area : Genetic Disease

    Study Phase : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    SparingVision's Lead Asset SPVN06 Clears IND Application in the US for the Treatment of Retinitis Pigmentosa

    Details : SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress which, acting synergistically, aim at slowing or stopping the degeneration of cone photoreceptors.

    Product Name : SPVN06

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    January 12, 2022

    Lead Product(s) : SPVN06

    Therapeutic Area : Genetic Disease

    Highest Development Status : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    SparingVision

    France arrow
    AAN
    Not Confirmed

    SparingVision

    France arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPVN06

    Therapeutic Area : Genetic Disease

    Study Phase : IND Enabling

    Sponsor : 4BIO Capital

    Deal Size : $51.9 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer

    Details : Proceeds from the financing will be primarily used to advance the development of SparingVision’s breakthrough treatment SPVN06 for the mutation-agnostic treatment of retinitis pigmentosa.

    Product Name : SPVN06

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    October 21, 2020

    Lead Product(s) : SPVN06

    Therapeutic Area : Genetic Disease

    Highest Development Status : IND Enabling

    Sponsor : 4BIO Capital

    Deal Size : $51.9 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    SparingVision

    France arrow
    AAN
    Not Confirmed

    SparingVision

    France arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPVN06

    Therapeutic Area : Ophthalmology

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retina...

    Details : SPVN06 uses a gene therapy-based approach independent of mutated genes and by a single subretinal injection of proprietary neurotrophic factors, aims at stopping and preventing the degeneration of photoreceptors leading to blindness.

    Product Name : SPVN06

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    June 30, 2020

    Lead Product(s) : SPVN06

    Therapeutic Area : Ophthalmology

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    SparingVision

    France arrow
    AAN
    Not Confirmed

    SparingVision

    France arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Teriparatide

    Therapeutic Area : Musculoskeletal

    Study Phase : Approved FDF

    Sponsor : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Pfenex Announces Enters New Partnership in Latin America, and Provides CRM197 Business Update

    Details : Adalvo recently entered into a commercialization agreement with a multinational pharmaceutical company to commercialize PF708, upon receipt of marketing authorization, in certain countries in Latin America.

    Product Name : Livogiva

    Product Type : Peptide

    Upfront Cash : Undisclosed

    June 26, 2020

    Lead Product(s) : Teriparatide

    Therapeutic Area : Musculoskeletal

    Highest Development Status : Approved FDF

    Sponsor : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth